Radiofrequency renal denervation safe, effective in largest US trial
Medtronic's Symplicity Spyral device showed significant blood pressure reductions in the SPIRAL AFFIRM study, meeting its 6-month primary endpoint. The study, involving 594 patients, reported an 18.2 mm Hg reduction in office systolic BP, exceeding the 6 mm Hg performance goal. The results were consistent across various subgroups and showed minimal adverse events, according to data presented at TCT 2026.
How this was made

The 30-second read
Why it matters
SPIRAL AFFIRM presented at TCT 2026 reports a statistically significant 6-month office systolic BP reduction of 18.2 mm Hg versus a prespecified 6 mm Hg performance goal, with no increase in antihypertensive medication burden and minimal adverse events through 6 months.
Market read
A large US trial readout that clears a prespecified BP performance goal can shift perceived clinical efficacy and safety risk for the device, influencing medtech adoption expectations.
What to watch
The article emphasizes office BP and secondary measures but does not detail longer-term durability beyond 6 months, adverse-event specifics, or how results translate into reimbursement and real-world procedure volumes.
Background
Radiofrequency renal denervation using the Symplicity Spyral catheter was FDA-approved for adults with uncontrolled hypertension, despite a slim FDA advisory panel vote questioning risk-benefit balance.
Ticker impact
Article names Medtronic’s Symplicity Spyral renal denervation catheter and reports SPIRAL AFFIRM results meeting the 6-month BP endpoint without medication escalation.
Likely positive sentiment for MDT as investors price improved evidence for renal denervation uptake and reimbursement discussions.
The piece is a pivotal-style efficacy/safety dataset (nearly 600-patient US cohort) tied to the specific device brand, which can shift perceived clinical risk versus earlier advisory-panel skepticism.
Market effects
Strengthens the interventional hypertension treatment evidence base, which could lift sentiment across renal denervation and cardiovascular device peers.
Primarily US-focused endpoint cohort details may influence US payer and guideline discussions.
International multicenter design and subgroup consistency may support broader global adoption narratives.
Counterpoint
FDA advisory panel previously voted that benefits did not outweigh risks; trial success may not fully resolve regulatory or payer skepticism, especially if endpoints or comparators are scrutinized.
Key entities
- companyMedtronic
Symplicity Spyral renal denervation catheter manufacturer referenced in the article.
- productSymplicity Spyral
Radiofrequency renal denervation catheter used in the SPIRAL AFFIRM study.
- clinical_studySPIRAL AFFIRM
Largest US cohort trial presented at TCT 2026 with a 6-month primary endpoint.
- regulatorFDA advisory panel
Previously voted by slim majority that benefits did not outweigh risks.


